Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

The PATRICIA study (NCT02536339) examined the efficacy and safety of pertuzumab plus high-dose trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) with progressive central nervous system (CNS) metastases following radiotherapy. Primary analysis confirmed CNS objective response...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Nancy U., Kumthekar, Priya, Sahebjam, Solmaz, Ibrahim, Nuhad, Fung, Anita, Cheng, Anna, Nicholas, Alan, Sussell, Jesse, Pegram, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656527/
https://www.ncbi.nlm.nih.gov/pubmed/37978197
http://dx.doi.org/10.1038/s41523-023-00587-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656527/
https://www.ncbi.nlm.nih.gov/pubmed/37978197
http://dx.doi.org/10.1038/s41523-023-00587-2

Ejemplares similares